A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors.
Wael A. Harb, Srinivasu Poondru(Center for Global Development), Hal W. Hirte(Juravinski Cancer Centre), Stuart Kaye(University of Wollongong), Susana Banerjee(Royal Marsden NHS Foundation Trust), A. Christinat, Richard T. Light, Margaret Singh, C. Sessa(Vita-Salute San Raffaele University), Ronit Simantov(Pfizer (United States)), David Sternberg(Daiichi Sankyo (United States))
Cited by 7
Related Papers
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers
|UCL Discovery (University College London)|1997|1k
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2011|580